ArticleFrontiers in medicine2025
Circulatory cathepsin K as biomarkers in older adults with sarcopenia: a case-control study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study explores the relationship between circulating cathepsin K (CatK) and cathepsin D (CatD) levels and sarcopenia in older adults. Methods: This case-control study included 343 participants aged more than 65 from Nanyang Central Hospital. Sarcopenia was diagnosed using AWGS criteria, requiring low handgrip strength (HGS) and reduced appendicular skeletal muscle mass (ASM). Fasting blood samples were collected to measure CatD and CatK levels via ELISA. The study compared these levels between groups and evaluated their diagnostic value using ROC curve analysis. Results: Serum CatK levels were significantly higher in participants with low HGS, low ASM, and sarcopenia (all Conclusion: Circulating CatK is a promising biomarker for sarcopenia, offering potential for early diagnosis and therapeutic targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.